Beg, Muhammad Shaalan

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Sangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 365

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Sangro, B., Kudo, M., Erinjeri, J. P., Qin, S., Ren, Z., Chan, S. L., Arai, Y., Heo, J., Mai, A., Escobar, J., et al. (2025) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 333

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 240

Liquid biopsy for cancer: review and implications for the radiologist

Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020) · Radiology

Cancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Cited by 87

Remote Monitoring and Data Collection for Decentralized Clinical Trials

Daly, B., Brawley, O. W., Gospodarowicz, M. K., Olopade, O. I., Fashoyin-Aje, L., Smart, V. W., Chang, I.-F., Tendler, C. L., Kim, G., Fuchs, C. S., et al. (2024) · JAMA Network Open

Telemedicine and Telehealth ImplementationStatistical Methods in Clinical Trials

Cited by 38

Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review

von Itzstein, M. S., Hullings, M., Mayo, H., Beg, M. S., Williams, E. L., & Gerber, D. E. (2021) · JAMA Oncology

Artificial Intelligence in Healthcare and EducationElectronic Health Records Systems

Cited by 36

Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway

Zhang, W., Bhagwath, A. S., Ramzan, Z., Williams, T. A., Subramaniyan, I., Edpuganti, V., Kallem, R. R., Dunbar, K. B., Ding, P., Gong, K., et al. (2021) · Molecular Cancer Therapeutics

PI3K/AKT/mTOR signaling in cancerEsophageal Cancer Research and Treatment

Cited by 33

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

Huffman, B. M., Basu Mallick, A., Horick, N. K., Wang-Gillam, A., Hosein, P. J., Morse, M. A., Beg, M. S., Murphy, J. E., Mavroukakis, S., Zaki, A., et al. (2023) · JAMA Network Open

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 25

Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments

Gerber, D. E., Sheffield, T. Y., Beg, M. S., Williams, E. L., Clark, V. L., Xie, Y., Holbein, M. E. B., Skinner, C. S., & Lee, S. J. C. (2021) · Journal of the National Comprehensive Cancer Network

COVID-19 and healthcare impactsEthics in Clinical Research

Cited by 23

Feasibility of institution‐agnostic, EHR‐integrated regional clinical trial matching

Shriver, S. P., Arafat, W., Potteiger, C., Butler, D. L., Beg, M. S., Hullings, M., Semy, S., Lister, Z., Khosama, L., Armstrong, S., et al. (2024) · Cancer

Electronic Health Records SystemsEthics in Clinical Research

Cited by 13